Literature DB >> 20485283

Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett's esophagus.

Justin B Taylor1, Joel H Rubenstein.   

Abstract

OBJECTIVES: Esophageal adenocarcinoma (EAC) is a devastating disease that has risen in incidence over the past several decades. Barrett's esophagus (BE) is an associated premalignant lesion. Current preventative efforts rely on endoscopic screening of individuals with gastroesophageal reflux disease (GERD) symptoms and surveillance endoscopy for those with BE. However, some recent studies have found a high prevalence of BE in patients without GERD, and others have found little or no association with GERD. We hypothesized that studies of higher-quality design show weaker associations of GERD with BE, and that GERD is only weakly associated with short-segment Barrett's esophagus (SSBE).
METHODS: We performed a systematic literature search in multiple online electronic databases regardless of language. Eligible studies required visualization of columnar mucosa and histological confirmation of intestinal metaplasia, and GERD symptoms ascertained by questionnaire or interview. The highest-quality sampling design was defined a priori by both cases and controls identified among unselected research volunteers ("research design") rather than by patients selected for endoscopy for clinical indications ("clinical design"), which introduces selection and ascertainment bias. A priori, heterogeneity was defined by Cochrane's Q P<0.20 and the inconsistency index (I(2); 25% low, 50% moderate, and 75% high). Heterogeneity of results can reflect significant differences in study design or effect modification by strata of outcomes.
RESULTS: Systematic review identified 13,392 citations. Evaluation identified 108 potentially relevant journal articles, of which 26 met eligibility. Of these, 14 studies identified cases of BE and controls based on clinical indication ("clinical design"), and 6 used the "research design." The remaining six studies identified cases of BE from patients undergoing endoscopy for clinical indication and controls among patients without known BE ("cases clinical/controls research"). The summary odds ratio (OR) for the association of GERD with BE from all studies was 2.90 (95% confidence interval (CI), 1.86-4.54), but the results were very heterogeneous (P=0.0001; I(2)=89%). When stratified by BE length and sampling design, the studies with clinical design showed substantial, but heterogeneous, associations with SSBE (OR, 2.38; 95% CI, 1.21-4.70; P=0.02; I(2)=62%), and stronger and homogeneous association with long-segment BE (LSBE; fixed effects OR, 2.96; 95% CI, 1.69-5.19; P=0.25; I(2)=25%). In the research study design, stratifying by length of BE resolved the heterogeneity and showed a strong association between GERD and LSBE (fixed effects OR, 4.92; 95% CI, 2.01-12.0; P=0.30; I(2)=19%) and no association with SSBE (fixed effects OR, 1.15; 95% CI, 0.763-1.73; P=0.84; I(2)=0%). Funnel plots showed potential evidence for bias against dissemination of small negative studies.
CONCLUSIONS: In the highest-quality studies, GERD symptoms are not associated with SSBE, but increased the odds of LSBE by fivefold. GERD symptoms can serve as a reliable predictor of LSBE, but not SSBE. If SSBE is considered worthy of identification, then current screening practices do not select patients at risk for endoscopy, and alternative methods of selection for screening need to be developed.

Entities:  

Mesh:

Year:  2010        PMID: 20485283      PMCID: PMC2916949          DOI: 10.1038/ajg.2010.194

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  46 in total

1.  Symptomatic gastro-oesophageal reflux as a risk factor for oesophageal adenocarcinoma.

Authors:  A J Cameron; Y Romero
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

Review 2.  Clinical practice. Barrett's Esophagus.

Authors:  Stuart Jon Spechler
Journal:  N Engl J Med       Date:  2002-03-14       Impact factor: 91.245

3.  Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal reflux.

Authors:  L B Gerson; R Edson; P W Lavori; G Triadafilopoulos
Journal:  Am J Gastroenterol       Date:  2001-07       Impact factor: 10.864

4.  Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms.

Authors:  M Voutilainen; P Sipponen; J P Mecklin; M Juhola; M Färkkilä
Journal:  Digestion       Date:  2000       Impact factor: 3.216

5.  Prevalence of Barrett's esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux.

Authors:  A Csendes; G Smok; P Burdiles; F Quesada; C Huertas; J Rojas; O Korn
Journal:  Dis Esophagus       Date:  2000       Impact factor: 3.429

6.  Risk factors for Barrett's esophagus: a case-control study.

Authors:  Massimo Conio; Rosangela Filiberti; Sabrina Blanchi; Roberto Ferraris; Santino Marchi; Paolo Ravelli; Gabriella Lapertosa; Gaetano Iaquinto; Renato Sablich; Riccardo Gusmaroli; Hugo Aste; Attilio Giacosa
Journal:  Int J Cancer       Date:  2002-01-10       Impact factor: 7.396

7.  Prevalence of Barrett's esophagus in asymptomatic individuals.

Authors:  Lauren B Gerson; Katerina Shetler; George Triadafilopoulos
Journal:  Gastroenterology       Date:  2002-08       Impact factor: 22.682

8.  Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma.

Authors:  Anna H Wu; Chiu-Chen Tseng; Leslie Bernstein
Journal:  Cancer       Date:  2003-09-01       Impact factor: 6.860

9.  Prevalence and clinical characteristics of Barrett's esophagus in a Chinese general population.

Authors:  Ping-Huei Tseng; Yi-Chia Lee; Han-Mo Chiu; Shih-Pei Huang; Wei-Chih Liao; Chien-Chuan Chen; Hsiu-Po Wang; Ming-Shiang Wu; Jaw-Town Lin
Journal:  J Clin Gastroenterol       Date:  2008 Nov-Dec       Impact factor: 3.062

10.  [Intestinal metaplasia at the esophagogastric junction. Prevelence and association in patients undergoing endoscopy].

Authors:  M L de Castro; C Fachal; J R Pineda; F Domínguez; J I R Prada; J A Hermo; J Suso; J Clofent
Journal:  Gastroenterol Hepatol       Date:  2002-10       Impact factor: 2.102

View more
  36 in total

1.  Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett's esophagus.

Authors:  Joel H Rubenstein; Hal Morgenstern; Daniel McConell; James M Scheiman; Philip Schoenfeld; Henry Appelman; Laurence F McMahon; John Y Kao; Val Metko; Min Zhang; John M Inadomi
Journal:  Gastroenterology       Date:  2013-08-30       Impact factor: 22.682

2.  Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process.

Authors:  Cathy Bennett; Nimish Vakil; Jacques Bergman; Rebecca Harrison; Robert Odze; Michael Vieth; Scott Sanders; Laura Gay; Oliver Pech; Gaius Longcroft-Wheaton; Yvonne Romero; John Inadomi; Jan Tack; Douglas A Corley; Hendrik Manner; Susi Green; David Al Dulaimi; Haythem Ali; Bill Allum; Mark Anderson; Howard Curtis; Gary Falk; M Brian Fennerty; Grant Fullarton; Kausilia Krishnadath; Stephen J Meltzer; David Armstrong; Robert Ganz; Gianpaolo Cengia; James J Going; John Goldblum; Charles Gordon; Heike Grabsch; Chris Haigh; Michio Hongo; David Johnston; Ricky Forbes-Young; Elaine Kay; Philip Kaye; Toni Lerut; Laurence B Lovat; Lars Lundell; Philip Mairs; Tadakuza Shimoda; Stuart Spechler; Stephen Sontag; Peter Malfertheiner; Iain Murray; Manoj Nanji; David Poller; Krish Ragunath; Jaroslaw Regula; Renzo Cestari; Neil Shepherd; Rajvinder Singh; Hubert J Stein; Nicholas J Talley; Jean-Paul Galmiche; Tony C K Tham; Peter Watson; Lisa Yerian; Massimo Rugge; Thomas W Rice; John Hart; Stuart Gittens; David Hewin; Juergen Hochberger; Peter Kahrilas; Sean Preston; Richard Sampliner; Prateek Sharma; Robert Stuart; Kenneth Wang; Irving Waxman; Chris Abley; Duncan Loft; Ian Penman; Nicholas J Shaheen; Amitabh Chak; Gareth Davies; Lorna Dunn; Yngve Falck-Ytter; John Decaestecker; Pradeep Bhandari; Christian Ell; S Michael Griffin; Stephen Attwood; Hugh Barr; John Allen; Mark K Ferguson; Paul Moayyedi; Janusz A Z Jankowski
Journal:  Gastroenterology       Date:  2012-04-24       Impact factor: 22.682

3.  The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma.

Authors:  William D Hazelton; Kit Curtius; John M Inadomi; Thomas L Vaughan; Rafael Meza; Joel H Rubenstein; Chin Hur; E Georg Luebeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-04-30       Impact factor: 4.254

4.  Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video).

Authors:  Anne F Peery; Toshitaka Hoppo; Katherine S Garman; Evan S Dellon; Norma Daugherty; Susan Bream; Alejandro F Sanz; Jon Davison; Melissa Spacek; Diane Connors; Ashley L Faulx; Amitabh Chak; James D Luketich; Nicholas J Shaheen; Blair A Jobe
Journal:  Gastrointest Endosc       Date:  2012-03-16       Impact factor: 9.427

5.  Metabolic syndrome increases risk of Barrett esophagus in the absence of gastroesophageal reflux: an analysis of SEER-Medicare Data.

Authors:  Jennifer Drahos; Winnie Ricker; Ruth Parsons; Ruth M Pfeiffer; Joan L Warren; Michael B Cook
Journal:  J Clin Gastroenterol       Date:  2015-04       Impact factor: 3.062

6.  Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.

Authors:  Reem Z Sharaiha; Daniel E Freedberg; Julian A Abrams; Y Claire Wang
Journal:  Dig Dis Sci       Date:  2014-05-03       Impact factor: 3.199

7.  A substantial incidence of silent short segment endoscopically suspected esophageal metaplasia in an adult Japanese primary care practice.

Authors:  Shouji Shimoyama; Toshihisa Ogawa; Toshiyuki Toma; Kousuke Hirano; Shuichi Noji
Journal:  World J Gastrointest Endosc       Date:  2012-02-16

Review 8.  Endoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma: Rationale, Candidates, and Challenges.

Authors:  Amrit K Kamboj; David A Katzka; Prasad G Iyer
Journal:  Gastrointest Endosc Clin N Am       Date:  2020-10-21

9.  Metabolic syndrome in relation to Barrett's esophagus and esophageal adenocarcinoma: Results from a large population-based case-control study in the Clinical Practice Research Datalink.

Authors:  Jennifer Drahos; Lin Li; Susan S Jick; Michael B Cook
Journal:  Cancer Epidemiol       Date:  2016-03-09       Impact factor: 2.984

10.  Prediction of Barrett's esophagus among men.

Authors:  Joel H Rubenstein; Hal Morgenstern; Henry Appelman; James Scheiman; Philip Schoenfeld; Laurence F McMahon; Valbona Metko; Ellen Near; Joan Kellenberg; Tal Kalish; John M Inadomi
Journal:  Am J Gastroenterol       Date:  2013-01-15       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.